Literature DB >> 9544801

Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.

N T Burford1, L M Tolbert, W Sadee.   

Abstract

Previous studies have shown that the agonist [D-Ala2, N-Me-Phe4, Gly-ol5]enkephalin (DAMGO) but not morphine induces mu-opioid receptor internalization [Arden, J.R., Segredo, V., Wang, Z., Lameh, J., Sadee, W., 1995. J. Neurochem. 65, 1636-1645]. In the present study we investigated the relationship between internalization of the mu-opioid receptor and the specific G proteins activated following treatment with morphine, DAMGO and endomorphin I (Tyr-Pro-Trp-Phe-NH2) (a putative endogenous mu-opioid receptor agonist) in human embryonic kidney (HEK) cells. Endomorphin I and DAMGO, but not morphine, caused mu-opioid receptor internalization. Morphine, DAMGO and endomorphin I each activated Gi1 alpha/Gi2 alpha, Go alpha and Gi3 alpha to a similar extent, but not Gq alpha/G11 alpha or Gs alpha in HEK membranes. Therefore, the three ligands tested differed in their ability to internalize mu-opioid receptors even though they were similar in activating individual G proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544801     DOI: 10.1016/s0014-2999(97)01556-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

1.  Lysophosphatidic acid-mediated Ca2+ mobilization in human SH-SY5Y neuroblastoma cells is independent of phosphoinositide signalling, but dependent on sphingosine kinase activation.

Authors:  K W Young; R A Challiss; S R Nahorski; J J MacKrill
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.

Authors:  E C Akam; R A Challiss; S R Nahorski
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

3.  Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.

Authors:  N Galeotti; C Ghelardini; A Bartolini
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

4.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

5.  Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation.

Authors:  Simona Patierno; Laura Anselmi; Ingrid Jaramillo; David Scott; Rachel Garcia; Catia Sternini
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

Review 6.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

7.  Agonist-dependent attenuation of mu-opioid receptor-mediated G-protein activation in the dorsal root ganglia of neuropathic rats.

Authors:  Ilona Obara; Ozge Gunduz Cinar; Katarzyna Starowicz; Sandor Benyhe; Anna Borsodi; Barbara Przewlocka
Journal:  J Neural Transm (Vienna)       Date:  2010-03-06       Impact factor: 3.575

8.  Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation.

Authors:  J A Trafton; C Abbadie; K Marek; A I Basbaum
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

9.  Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins.

Authors:  A M Carruthers; A J Warner; A D Michel; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 10.  Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications.

Authors:  N T Burford; J R Traynor; A Alt
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.